Last reviewed · How we verify
AG regimen
AG regimen is a chemotherapy combination regimen, typically consisting of adriamycin (doxorubicin) and gemcitabine, that works by damaging cancer cell DNA and inhibiting nucleotide synthesis to kill rapidly dividing cells.
AG regimen is a chemotherapy combination regimen, typically consisting of adriamycin (doxorubicin) and gemcitabine, that works by damaging cancer cell DNA and inhibiting nucleotide synthesis to kill rapidly dividing cells. Used for Soft tissue sarcoma (Phase 3), Other solid tumors (investigational).
At a glance
| Generic name | AG regimen |
|---|---|
| Also known as | Nab-paclitaxel and Gemcitabine |
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The AG regimen combines two cytotoxic chemotherapy agents: adriamycin (doxorubicin), a topoisomerase II inhibitor that intercalates into DNA and causes strand breaks, and gemcitabine, a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA to disrupt replication. Together, these agents provide complementary mechanisms to maximize cancer cell death across multiple phases of the cell cycle.
Approved indications
- Soft tissue sarcoma (Phase 3)
- Other solid tumors (investigational)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Cardiotoxicity (doxorubicin-related)
- Alopecia
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) (PHASE2)
- Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- A Phase III Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer (PHASE2)
- IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer (PHASE2)
- Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer (NA)
- HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AG regimen CI brief — competitive landscape report
- AG regimen updates RSS · CI watch RSS
- Tianjin Medical University Cancer Institute and Hospital portfolio CI